Catherine Prady

1.7k total citations
22 papers, 209 citations indexed

About

Catherine Prady is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Catherine Prady has authored 22 papers receiving a total of 209 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 3 papers in Economics and Econometrics. Recurrent topics in Catherine Prady's work include HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (9 papers) and Advanced Breast Cancer Therapies (8 papers). Catherine Prady is often cited by papers focused on HER2/EGFR in Cancer Research (10 papers), Cancer Treatment and Pharmacology (9 papers) and Advanced Breast Cancer Therapies (8 papers). Catherine Prady collaborates with scholars based in Canada, United States and United Kingdom. Catherine Prady's co-authors include Nassera Touati, Dominique Tremblay, Karine Bilodeau, Marco Bruzzone, Zbigniew Nowecki, Jamil Asselah, Susan Dent, Noam Pondé, Kylea Potvin and Susan Ellard and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Catherine Prady

20 papers receiving 205 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Prady Canada	10	132	53	45	32	24	22	209
Amanda R. Kahl United States	10	167 1.3×	45 0.8×	20 0.4×	25 0.8×	16 0.7×	33	291
Lucy Guerra United States	9	128 1.0×	33 0.6×	29 0.6×	40 1.3×	19 0.8×	24	243
Eva González-Haba Spain	9	152 1.2×	46 0.9×	62 1.4×	37 1.2×	17 0.7×	31	283
Jared D. Acoba United States	12	171 1.3×	50 0.9×	80 1.8×	43 1.3×	45 1.9×	39	345
Mary Helen Hackney United States	10	102 0.8×	27 0.5×	33 0.7×	26 0.8×	33 1.4×	20	245
Madison Grogan United States	10	190 1.4×	65 1.2×	33 0.7×	16 0.5×	31 1.3×	30	268
Hagar Elghazawy Egypt	9	182 1.4×	60 1.1×	25 0.6×	14 0.4×	18 0.8×	19	284
Shira Peleg Hasson Israel	9	143 1.1×	50 0.9×	43 1.0×	33 1.0×	57 2.4×	26	272
Joshua J. McFarlane United States	7	109 0.8×	96 1.8×	43 1.0×	19 0.6×	45 1.9×	8	240
Christopher Su United States	11	149 1.1×	114 2.2×	44 1.0×	29 0.9×	41 1.7×	30	297

Countries citing papers authored by Catherine Prady

Since Specialization

Citations

This map shows the geographic impact of Catherine Prady's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Prady with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Prady more than expected).

Fields of papers citing papers by Catherine Prady

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Prady. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Prady. The network helps show where Catherine Prady may publish in the future.

Co-authorship network of co-authors of Catherine Prady

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Prady. A scholar is included among the top collaborators of Catherine Prady based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Prady. Catherine Prady is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmid, Peter, Hao‐Chien Wang, Y.H. Park, et al.. (2025). 555MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment (tx) for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Final results from the phase Ib/II BEGONIA study. Annals of Oncology. 36. S413–S414. 1 indexed citations

Corbière, Marc, et al.. (2024). Validation of the Return-to-Work Obstacles and Self-Efficacy Scale for Women on Sick Leave Due to Breast Cancer (ROSES-BC). Journal of Occupational Rehabilitation. 34(4). 818–831. 1 indexed citations

Tremblay, Dominique, et al.. (2024). Bouncing Beyond Adversity in Oncology: An Exploratory Study of the Association Between Professional Team Resilience at Work and Work-Related Sense of Coherence. Current Oncology. 31(11). 7287–7300. 1 indexed citations

Schmid, Peter, Piotr J. Wysocki, X. Cynthia, et al.. (2023). 379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. Annals of Oncology. 34. S337–S337. 25 indexed citations

Schmid, Peter, Piotr J. Wysocki, X. Cynthia, et al.. (2023). Abstract PD11-09: PD11-09 Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study. Cancer Research. 83(5_Supplement). PD11–9. 10 indexed citations

Tremblay, Dominique, Nassera Touati, Kelley Kilpatrick, et al.. (2022). Building resilience in oncology teams: Protocol for a realist evaluation of multiple cases. PLoS ONE. 17(5). e0268393–e0268393. 8 indexed citations

Latreille, Jean, Isabelle Germain, Roger Grégoire, et al.. (2021). Prioritizing surgery during the COVID-19 pandemic: the Quebec guidelines. Canadian Journal of Surgery. 64(1). E103–E107. 15 indexed citations

Tremblay, Dominique, et al.. (2021). Risk-Stratified Pathways for Cancer Survivorship Care: Insights from a Deliberative Multi-Stakeholder Consultation. Current Oncology. 28(5). 3408–3419. 12 indexed citations

Tremblay, Dominique, Nassera Touati, Thomas G. Poder, et al.. (2019). Collaborative governance in the Quebec Cancer Network: a realist evaluation of emerging mechanisms of institutionalization, multi-level governance, and value creation using a longitudinal multiple case study design. BMC Health Services Research. 19(1). 752–752. 14 indexed citations

10.

Zanotti, Giovanni, Mihaela Mates, Julie Lemieux, et al.. (2018). Real-World Patient- and Caregiver-reported Outcomes in Advanced Breast Cancer. Current Oncology. 25(4). 282–290. 13 indexed citations

11.

Martel, Samuel, et al.. (2018). Adherence to Guidelines in Requesting Oncotype DX in a Publicly Funded Health Care System. Current Oncology. 25(4). 311–318.

12.

Martel, Samuel, Marco Bruzzone, Marcello Ceppi, et al.. (2017). Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. 62. 123–132. 17 indexed citations

13.

Tremblay, Dominique, Catherine Prady, Karine Bilodeau, et al.. (2017). Optimizing clinical and organizational practice in cancer survivor transitions between specialized oncology and primary care teams: a realist evaluation of multiple case studies. BMC Health Services Research. 17(1). 834–834. 13 indexed citations

14.

Zanotti, Giovanni, Ritesh Banerjee, Mihaela Mates, et al.. (2016). A Real-World Outcome Research Study On Quality of Life, Work Productivity And Healthcare Resource Utilization In Metastatic Breast Cancer For Patients And Caregivers. Value in Health. 19(7). A616–A616. 2 indexed citations

15.

Rayson, Daniel, Sasha Lupichuk, Kylea Potvin, et al.. (2016). Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer. Breast Cancer Research and Treatment. 157(1). 109–116. 39 indexed citations

16.

Piwko, Charles, et al.. (2015). Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. Clinical Drug Investigation. 35(8). 487–493. 5 indexed citations

17.

Bachelot, Thomas, José Á. García-Sáenz, Sunil Verma, et al.. (2014). Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. BMC Cancer. 14(1). 166–166. 19 indexed citations

18.

Bachelot, Thomas, Aňa Lluch, Catherine Prady, et al.. (2009). Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.. Cancer Research. 69(2_Supplement). 4115–4115. 3 indexed citations

19.

Blay, Jean‐Yves, Aňa Lluch, Catherine Prady, et al.. (2009). 5003 Phase II study of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: activity and safety results. European Journal of Cancer Supplements. 7(2). 260–261. 3 indexed citations

20.

Blay, Jean‐Yves, Aňa Lluch, Miguel Martín, et al.. (2009). Sunitinib (SU) in Combination with Trastuzumab (T) for the Treatment of Advanced Breast Cancer (ABC): Activity and Safety Results from a Phase II Study.. Cancer Research. 69(24_Supplement). 201–201. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact